Symbols

MESO

Mesoblast·NASDAQ

--(--)

MESO fundamentals

MESO Q2 2026 Earnings

Mesoblast (MESO) released its earnings on Feb 27, 2026: revenue was 51.34M (YoY --), missed estimates; EPS was -0.311 (YoY --), missed estimates.

Revenue / YoY

51.34M

EPS / YoY

-0.311

Report date

Feb 27, 2026

MESO Earnings Call Summary for Q2,2026

Ryoncil Growth: FY 2026 revenue guidance of $110-120 million, with 49 centers onboarded and 20% market share target by year-end.
Financial Strength: $130 million cash on hand and $125 million credit facility to support growth.
Pipeline Momentum: Rexlemestrocel-L Phase III enrollment complete; Revascor BLA filing for full approval in Q2 2026.
Strategic Expansion: Adult GVHD trial underway, targeting a 3x larger market than pediatric GVHD.

Earnings

EPS

Revenue

Revenue & Expenses

MESO has released its 2023 Q4 earnings report, with revenue of 2.14M, reflecting a YoY change of -3.82%, and net profit of -21.92M, showing a YoY change of -2.16%. The Sankey diagram below clearly presents MESO's revenue sources and cost distribution.

Key Indicators

Mesoblast (MESO) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Mesoblast (MESO)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Mesoblast (MESO)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Mesoblast (MESO)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown